Homologous reactivity; clade 1 viruses The percentage of subjects with antibody titres ≥20 against NIBRG14 varied significantly ( P = 0·008) between the dose/formulation groups because of an increasing trend with dose within the adjuvanted group (24% to 42% to 61%) but not within the no adjuvant group ( Table 1 ).
← all excerpts
Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.
2
—
—
The sentences
This was statistically significant ( P < 0·02) for NIBRG23 and A/turkey/Turkey/1/2005 but numbers were too small to see a significant trend for Ind/5/05/RG2 and A/Indonesia/5/2005.